Clindamycin is an antibiotic by choose, because of its wade distribution into organs and tissues, it is used in the treatment of osteomyelitis, however the owners of dogs does not have the discipline necessary to complete the treatment, affecting therapeutic response. The innovation of polymeric matrix made of hydroxypropylmethylcellulose (HPMC) + poloxamer 188 and/or made of HPMC + carbopol with the addition of clindamycin will result in modified release formulations, increasing therapeutic concentration time in serum, and decreasing dosing frequency. Two formulations of 20 mg/Kg orally made of HPMC with poloxamer 188 and HPMC with carbopol were designed; they were compared with a control treatment of clindamycin without excipients. The sanguineous concentrations of clindamycin were determined by blood samples take it until complete sixty hours. The clindamycin concentration in the serum was determined by the diffusion method in Bennet agar, and the pharmacokinetic analysis was made with the software PKAnalyst. The results were analyzed by the ANOVA test, and the difference between the groups was analyzed by the Tukey test. An innovative clindamycin design of controlled released was achieve, thanks to the addition of the excipients based on a polymeric matrix in their formulations.